Study S002148

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VK2735, a Dual Glucagon-like Peptide-1 and Gastric Inhibitory Polypeptide Receptor Agonist, in Healthy Adults and Otherwise Healthy Adults Who Have an Increased Body Mass Index

ClinicalTrials.gov record

Registration

Registration: NCT05203237
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 92
Start: 2021-12-14
Primary completion: 2024-11-04
Lead sponsor: Viking Therapeutics, Inc.
Conditions: Weight Loss; NASH
Interventions: BIOLOGICAL:VK2735; BIOLOGICAL:Placebo; DRUG:VK2735 Placebo; DRUG:VK2735 Drug
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious AEs (TESAEs) [8 days]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.